Eisai pledges $200M to back new cancer R&D ops
An ambitious new cancer R&D operation launched in Cambridge, MA late last week. H3 says that it has gained a pledge of up to $200 million from Japan's Eisai to back its work on developing new personalized cancer therapies. The H3 group will build on the work of its prominent scientific founders, Stuart L. Schreiber, PhD, and Todd R. Golub, MD, founding members of the Broad Institute of Harvard and MIT. Kentaro Yoshimatsu, PhD, who serves as CSO of Eisai Product Creation Systems, will take on the additional role of president of H3 Biomedicine. Release
Comments